2 weeks Ago By Defense World Staff
Shares of Bristol-Myers Squibb ( NYSE:BMY – Get Free Report ) have earned an average rating of “Hold” from the seventeen research firms that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating and two have assigned a buy rating to the company.
The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $55.00. A number of equities analysts have recently weighed in on the company.
Cantor Fitzgerald reiterated a “neutral” rating and issued a $50.00 target price on shares of Bristol-Myers Squibb in a report on Monday, September 16th. BMO Capital Markets reiterated a “market perform” rating and issued a $48.
00 target price on shares of Bristol-Myers Squibb in a research report on Monday, September 23rd. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Bristol-Myers Squibb from $53.00 to $45.
00 and set a “hold” rating on the stock in a report on Tuesday, July 23rd. TD Cowen increased their price objective on Bristol-Myers Squibb from $45.00 to $53.
00 and gave the stock a “hold” rating in a report on Monday, August 12th. Finally, Jefferies Financial Group boosted their target price on Bristol-Myers Squibb from $49.00 to $51.
00 and gave the company a “hold” rating in a research note on Wednesday, August 28th. Check Out Our Latest Stock Report on BMY Hedge Funds Weigh In On Bristol-Myers Squibb Bristol-Myers Squibb Price Performance NYSE BMY opened at $50.91 on Monday.
The company has a current ratio of 1.16, a quick ratio of 1.02 and a debt-to-equity ratio of 2.
86. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $58.
46. The company has a market cap of $103.20 billion, a PE ratio of -16.
42, a PEG ratio of 12.96 and a beta of 0.46.
The stock’s 50-day moving average price is $48.53 and its two-hundred day moving average price is $46.28.
Bristol-Myers Squibb ( NYSE:BMY – Get Free Report ) last posted its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.
64 by $0.43. The firm had revenue of $12.
20 billion for the quarter, compared to analysts’ expectations of $11.54 billion. Bristol-Myers Squibb had a negative net margin of 14.
06% and a positive return on equity of 12.51%. The company’s quarterly revenue was up 8.
7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.75 EPS.
On average, analysts predict that Bristol-Myers Squibb will post 0.77 EPS for the current year. Bristol-Myers Squibb Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Friday, November 1st.
Investors of record on Friday, October 4th will be paid a $0.60 dividend. The ex-dividend date is Friday, October 4th.
This represents a $2.40 dividend on an annualized basis and a yield of 4.71%.
Bristol-Myers Squibb’s payout ratio is presently -77.42%. About Bristol-Myers Squibb ( Get Free Report Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. Recommended Stories Five stocks we like better than Bristol-Myers Squibb How to Use High Beta Stocks to Maximize Your Investing Profits Simon Property REIT: A Safe Bet for Growth and Steady Dividends What to Know About Investing in Penny Stocks CarMax’s Impressive Rally: What Investors Should Watch Next Dividend Screener: How to Evaluate Dividend Stocks Before Buying MarketBeat Week in Review – 9/23 – 9/27 Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.
com's FREE daily email newsletter ..
